In time, the work could help to identify the many forms of autism that make up the spectrum. This is crucial information when those with ASD are administered drugs for a clinical trial. If a gene variant occurs only in one subset of people with ASD but a drug that compensates for that variant is tested across a broader spectrum, then the drug “would appear to be a failure even if it responded to everyone it was meant to respond to,” says Greg Farber, director of technology, development and co-ordination at the U.S. National Institute of Mental Health in Bethesda, Md.Learn more:

Questions? Contact Us!

Can't find what you're looking for? Contact Us